11.2 Managing Complications: Bleeding, Allergy, Adverse Events & Scarring
Key Takeaways
- Control bleeding after debridement in steps: direct pressure, calcium alginate or oxidized cellulose, silver nitrate for small vessels, topical thrombin or tranexamic acid, then electrocautery or suture ligation; minor debridement can usually proceed without stopping anticoagulants when local hemostasis is available.
- Allergic contact dermatitis (a delayed type IV reaction) spreads beyond the contact area, itches, and is confirmed by patch testing read at about day 2 and day 4, while irritant dermatitis stays within the exposed area; common wound allergens include neomycin, bacitracin, fragrances, lanolin, rubber accelerators, and colophony in adhesives.
- Immediate type I reactions such as anaphylaxis to chlorhexidine or latex need emergency treatment with intramuscular epinephrine, allergen removal, and documentation of the allergy.
- Medical adhesive-related skin injury includes skin stripping, tension blisters, and irritant or allergic dermatitis, and it is prevented with barrier films, silicone adhesives, tension-free application, and slow, low-angle removal with adhesive removers.
- Hypertrophic scars stay within the wound borders and often improve over time, whereas keloids extend beyond the original wound and recur after excision; silicone gel or sheeting and pressure therapy are first-line prevention, and intralesional triamcinolone is a mainstay of keloid treatment.
11.2 Managing Complications: Bleeding, Allergy, Adverse Events & Scarring
Core Clinical Principle: Every wound treatment can cause harm. Wound specialists must prevent, recognize, and manage bleeding, allergic reactions, device and drug adverse events, and abnormal scarring, and they must document and report these events so that patients and systems learn from them.
The CWSP task list asks candidates to manage bleeding, allergic reactions, adverse events, scarring, and infection. Infection, biofilm, and systemic barriers to healing are covered in their own sections; this section focuses on the remaining complications.
Bleeding
Hemostasis Ladder After Debridement
| Step | Method | Notes |
|---|---|---|
| 1 | Direct pressure with elevation for 5 to 10 minutes | Controls most capillary oozing |
| 2 | Hemostatic dressings: calcium alginate, oxidized regenerated cellulose, gelatin or collagen sponges | Alginate calcium ions support clotting |
| 3 | Silver nitrate for pinpoint bleeders and hypergranulation | Painful; stains tissue black |
| 4 | Topical thrombin, fibrin sealants, or tranexamic acid-soaked gauze | Useful for diffuse oozing and malignant wounds |
| 5 | Electrocautery or suture ligation | For named or pulsatile vessels |
| 6 | Operating room or interventional radiology | For uncontrolled or arterial bleeding |
Topical epinephrine-soaked gauze constricts vessels but should be avoided on ischemic digits and flaps.
Patients Taking Anticoagulants or Antiplatelet Drugs
- Minor bedside debridement can usually proceed without stopping warfarin, direct oral anticoagulants, or antiplatelet agents when local hemostatic measures are ready, because stopping them raises thrombotic risk.
- Check the INR for patients on warfarin before larger procedures, and coordinate interruption and bridging with the prescriber for surgical excision under anesthesia.
- Use gentler methods (autolytic, enzymatic, or conservative sharp debridement) when coagulopathy is severe, such as with thrombocytopenia or liver failure.
Warning Signs of Serious Bleeding
- A sentinel bleed from a groin, neck, or bypass graft wound may precede catastrophic rupture of an infected vessel or pseudoaneurysm; treat it as an emergency.
- Bleeding under NPWT can be hidden in the canister; FDA safety communications describe serious bleeding and deaths, especially with anticoagulation and exposed vessels or grafts.
- Friable, easily bleeding granulation can signal infection, and bleeding from a malignant wound needs palliative hemostasis planning.
Allergic and Irritant Reactions
| Feature | Irritant Contact Dermatitis | Allergic Contact Dermatitis (Type IV) | Immediate Hypersensitivity (Type I) |
|---|---|---|---|
| Mechanism | Direct chemical or physical damage | T-cell-mediated sensitization | IgE-mediated mast cell release |
| Timing | Minutes to hours; any exposed person | 24 to 72 hours after exposure in a sensitized person | Minutes |
| Appearance | Erythema, burning, confined to the exposed area | Itchy, weeping, vesicular eczema that spreads beyond the contact area | Hives, swelling, wheeze, hypotension |
| Examples | Exudate, adhesives, antiseptics, incontinence | Neomycin, bacitracin, fragrances, lanolin, rubber accelerators, colophony in adhesives, some topical corticosteroids | Chlorhexidine, latex, some antibiotics |
| Management | Remove the irritant; barrier film | Stop the allergen; topical corticosteroid; patch test | Stop exposure; intramuscular epinephrine; emergency care |
Patients with leg ulcers and stasis dermatitis have high rates of contact sensitization. Patch testing applies standardized allergens under occlusion, with readings at about 48 hours and again around 96 hours. Record confirmed allergies prominently, and choose fragrance-free, lanolin-free products.
Medical Adhesive-Related Skin Injury (MARSI)
- Types: Epidermal stripping, tension blisters (from tape applied under stretch or over swelling), skin tears, maceration, folliculitis, and irritant or allergic dermatitis.
- Prevention: Use no-sting barrier films, choose silicone adhesives for fragile skin, apply tape without tension, allow for swelling, and remove dressings slowly, low and parallel to the skin, supporting the skin and using a medical adhesive remover.
Adverse Events From Wound Therapies
| Therapy | Examples of Adverse Events |
|---|---|
| Compression | Pressure damage, necrosis, and amputation in unrecognized arterial disease |
| Total contact casting | Cast-induced ulcers, falls, and missed infection |
| NPWT | Bleeding, retained foam pieces, periwound damage, infection |
| Hyperbaric oxygen | Middle ear barotrauma, temporary myopia, oxygen toxicity seizures, confinement anxiety |
| Topical and systemic drugs | Iodine absorption and thyroid effects, argyria, mafenide acidosis, drug rashes, Stevens-Johnson syndrome |
| Procedures | Hematoma, nerve injury, infection, pain crises |
When an adverse event occurs: treat the patient, stop or change the suspected cause, disclose the event honestly to the patient, document objectively, report it through the facility safety system, and report serious drug or device problems to the FDA through MedWatch. The Joint Commission considers a stage 3, stage 4, or unstageable pressure injury acquired after admission to be a sentinel event that warrants review.
Scarring
| Feature | Hypertrophic Scar | Keloid |
|---|---|---|
| Borders | Stays within the original wound | Extends beyond the original wound |
| Timing | Usually within weeks of injury | Can appear months later |
| Course | Often regresses partly over 1 to 2 years | Rarely regresses; frequently recurs after excision |
| Risk factors | Tension across joints, deep dermal injury, healing longer than about 3 weeks (as in burns), infection | Genetic predisposition, darker skin types, ear lobes, chest, shoulders |
Prevention and treatment:
- Silicone gel or sheeting: First-line prevention and treatment, worn for many hours a day for at least 2 to 3 months once the wound is epithelialized.
- Pressure garments: Standard after major burns, worn most of the day for many months.
- Intralesional corticosteroid (triamcinolone): Mainstay for keloids and thick hypertrophic scars; may be combined with 5-fluorouracil.
- Laser, cryotherapy, and surgery: Pulsed-dye or fractional laser for redness and texture; excision of keloids needs adjuvant steroid or radiation to reduce recurrence.
- Contracture: Positioning, splinting, stretching, and surgical release with Z-plasty or grafts.
- Sun protection: Prevents hyperpigmentation of new scars.
Mature scar reaches only about 80% of the tensile strength of uninjured skin, and chronic unstable scars carry a small risk of malignant change (Marjolin ulcer), so a scar that ulcerates repeatedly should be biopsied.
Clinical Traps
Trap 1: Stopping Anticoagulants for Minor Debridement
Stopping a direct oral anticoagulant for a bedside debridement exposes a patient with atrial fibrillation to stroke risk for little benefit. Plan local hemostasis instead.
Trap 2: Excising a Keloid Alone
Simple excision of a keloid without adjuvant treatment often leads to a larger recurrence.
A 29-year-old man has a firm, raised, itchy scar on his earlobe that appeared 5 months after ear piercing, has grown well beyond the original puncture site, and has not regressed. What is the most likely diagnosis and appropriate first-line treatment?
A 78-year-old woman taking apixaban for atrial fibrillation needs bedside sharp debridement of adherent slough from a 6 cm² venous leg ulcer. Which approach to bleeding risk is most appropriate?
A 70-year-old man develops large, clear tense blisters along the edges of a tape-secured dressing placed over his swollen knee after surgery. The skin under the dressing center is intact, and the blisters are aligned with the direction the tape was stretched. What is the most likely cause, and how can it be prevented?